Horn Howard sold $156K of RARE

Horn Howard (Chief Financial Officer) sold 4,698 shares of Ultragenyx Pharmaceutical Inc. (RARE) at $33.13 ($0.16M total) on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Horn Howard
Published Jul 6, 2026, 7:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 7:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RARE
Neutral
high confidence
Mentioned
$RARE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RARENeutralLow
01

Why it matters

The disclosure updates the insider trading record but does not, by itself, indicate a new fundamental development for Ultragenyx.

02

Market read

Traders may treat this as routine insider activity; absent other catalysts, it is unlikely to drive a directional trade.

03

What to watch

The article provides only the sale details; it does not include any concurrent company news (earnings, guidance, trial updates) that would contextualize the sale.

Relevance 3/10Novelty 3/10Timing: Filed July 6, 2026; sale executed July 1, 2026.

Background

This is an SEC Form 4 insider transaction for Ultragenyx Pharmaceutical Inc., reported by CFO Horn Howard.

Company-level read

Ticker impact

$RARENeutralHigh confidence
Context

Horn Howard, Ultragenyx’s CFO, sold 4,698 shares in an open-market transaction under a 10b5-1 plan, totaling $155,644.74.

Expected impact

Low likelihood of a near-term price move driven solely by this Form 4 sale.

Evidence & confidence

The filing is a disclosed insider sale (not a buy), but it is explicitly under a Rule 10b5-1 plan, which reduces the immediacy/interpretability of the signal.

Market effects

Minimal—this is company-specific insider transaction disclosure with no stated operational/regulatory/clinical catalyst.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with valuation or liquidity needs; traders may still watch for follow-on insider activity.

Key entities

  • Ultragenyx Pharmaceutical Inc.

    RARE; subject of the Form 4 insider sale disclosure.

  • Horn Howard

    CFO who executed an open-market sale under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RAREMed

Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy

Ultragenyx Pharmaceutical Inc (RARE) discontinued two gene therapy programs (GTX-102 and UX701) due to efficacy and trial advancement issues. The company is restructuring, cutting 20% of its workforce. The future of setrusumab for osteogenesis imperfecta is uncertain pending FDA discussions. R&D spending for 2027 is guided at less than $350 million, with a focus on commercial products. The company faces potential competition in the Sanfilippo syndrome type A market.

$RAREHighAI 8/10

Ultragenyx (RARE) Q3 2026 Earnings Call Transcript

Ultragenyx (RARE) reported Q3 2026 earnings, highlighting FDA approvals for GENGLYCOS and FAYUVI, two new gene therapies. The company also announced setbacks in clinical trials for GTX-102 and UX701, leading to program terminations and workforce reductions. Revenue guidance for 2026 was reaffirmed at $730M-$760M, with profitability expected in 2027. The company aims to reduce expenses by 50% by 2027.